



GIONAL OFFICE FOR EUROPE



Organisation mondiale de la Santé

BUREAU REGIONAL DE L'EUROPE



Weltgesundheitsorganisation

REGIONALBURO FUR EUROPA



Всемирная организация здравоохранения

Европейское региональное бюро

GVIRF Johannesburg March

Vaccine Hesitancy: what it means and what we need to know in order to tackle it.

Robb Butler Programme Manager Vaccine-preventable Diseases and Immunization VPI/DCE

Vaccination hesitancy ?


- Refers to delay in acceptance or refusal of vaccines despite availability of vaccine services.
- Is complex and context specific varying across time, place and vaccines.
- Is influenced by factors such as complacency, convenience and confidence.

Sage Vaccine Hesitancy Working Group & Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP), Butler and MacDonald


Journal of Vaccine, 2015.




Vaccine Hesitancy Model













Today, anecdote often wins over fact





Sensationalist emotional stories have impact





Sources: Organic Trade Association, 2011 Organic Industry Survey, U.S. Department of Education, Office of Special Education Programs, Data Analysis System (DANS), OM 8# 1820-0043: "Children with Disabilities Receiving Special Education Under Part B of the Individuals with Disabilities Education Act



BIG VACCINE PRIZE ON THE NEWS

The Royal Bank of Scotland pic

12.06.09

24,951,269,40

She won lotto big prize after HEPATITIS B vaccination
"It was just after the 2nd shot", she said

Tearrity four endlines, sine hundred and siny one thousand,

- hundred and sixty sine pounds and forty prints only

Brian & Joan Caswell







Figure 1. Recommended immunization schedule for persons aged 0 through 18 years – United States, 2014. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE (FIGURE 2)).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are in bold.

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16-18 yrs
Hepatitis B' (HepB)	1+dose	< _2=	dose>		•		-3+ dose -		*							
Rotavirus ² (RV) RV1 (2-dose series); RV5 (3-dose series)			1 ^e dose	2 nd dose	See footnote 2											
Diphtheria, tetanus, & acel- Iular pertussis: (DTaP: <7 yrs)			1+dose	2 ^{rel} diose	3 rd dose		50. 	~ _4*	dose			5ª dose				
Tetanus, diphtheria, & acel- Iular pertussis ⁴ (Tdap: <u>></u> 7 yrs)														(3dap)		
Haemophilus influenzae type b ^a (Hib)			1*dose	2#dose	See footnote 5		3ª or 4 See foo	otnote 5								
Pneumococcal conjugate ^a (PCV13)			1*dose	2+dose	3 rd dose		<u>←</u> 4*(dose →								
Pneumococcal polysaccha- ride# (PPSV23)																
Inactivated poliovirus ⁷ (IPV) (<18 yrs)			1*dose	2 rd dose	•		-3 rd ose		•			4ª dose				
Influenzat (IV; LAIV) 2 doses for some: See footnote 8					Annual vaccination (IV only)						Annual vaccination (IV or LAIV)					
Measles, mumps, rubella ^a (MMR)							<mark>←</mark> 1*c	tose →				2+idose				
Varicella** (VAR)							< <u>−</u> 1+0	tose 🔶				2*idose				
Hepatitis A ¹¹ (HepA)							 2	dose series,	See footnote	11 						
Human papillomavirus ¹² (HPV2: females only; HPV4: males and females)														(3-dose series)		
Meningococcal [™] (Hib-Men- CY ≥ 6 weeks; MenACWY-D ≥9 mos; MenACWY-CRM ≥ 2 mos)						See too	tnote 13							1ªdose		Socie
Range of recommended ages f all children	or	ages	e of recom for catch-u inization	mended p		Range o ages for groups	f recomme certain hig	nded h-risk		during w	f recommend which catch ged and for groups	-up is	[mmende	

This schedule includes recommendations in effect as of January 1, 2014. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at http://www.cdc.gov/vaccines/ncp/acg-necs/index.html. Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online (http://www.caes.hhs.gov) or by telephone (800-822-7967) Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online (http://www.cdc.gov/vaccines/vac-adminicontraindications.html) or by telephone (800-CDC-NFO (800-222-4636)).

This schedule is approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/vaccines/acip), the American Academy of Pediatrics (http://www.aap.org), the American Academy of Family Physicians (http://www.aafp.org), and the American College of Obstetrictans and Gynecologists (http://www.acog.org).

NOTE: The above recommendations must be read along with the footnotes of this schedule.

With that in mind.....

SAGE Vaccine Hesitancy Working Group, the scale of vaccine hesitancy and threat it poses

Research/diagnostic tool developed to diagnose vaccine hesitancy at national, provincial, district and locals levels

